Market narrative

Read the headlines around the signals.

Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.

Latest fool.com · about 18 hours ago

Why Rivian Is Poised to Soar. Hint: It's Not All R2 Hype.

Rivian's investor focus is largely on the R2 launch and ramp-up, but don't overlook its staggering margins in software and services that are helping offset early R2 launch costs.

Stocks

More recent coverage

Page 96
BTMD marketbeat.com · about 18 hours ago

biote Q2 Earnings Call Highlights

biote NASDAQ: BTMD reported lower second-quarter revenue and a net loss as a voluntary recall of certain hormone pellets supplied by Asteria Health disrupted procedure volumes, while management said supply conditions have since normalized and should support sequential improvement in the second half of 2026.

BYND marketbeat.com · about 18 hours ago

Beyond Meat Q2 Earnings Call Highlights

Beyond Meat NASDAQ: BYND reported second-quarter 2026 revenue above its guidance range as international retail growth partially offset continued weakness in U.S. channels and international food service. Management said the company is pursuing a turnaround centered on expanding in Europe and Canada, entering adjacent nutrition categories, and improving operating efficiency.

CAI marketbeat.com · about 18 hours ago

Caris Life Sciences Q2 Earnings Call Highlights

Caris Life Sciences NASDAQ: CAI reported record clinical volume and raised its full-year revenue outlook after second-quarter revenue increased 45% from a year earlier, driven by growth in molecular profiling services, higher average selling prices and an expanding commercial organization.

← Newer
Older →